High-throughput biomarker analysis delivers maximum information from each sample

Quotient Bioresearch highlights new approach at World Congress

CAMBRIDGE UK, 03 June 2009. At the recent Biomarker World Congress 2009, held in Philadelphia, USA, 27 – 29 May, Dr Craig Stovold, Senior Project Manager-Bioanalytical Sciences, Quotient Bioresearch, reported on how the company’s multiplexed assays are delivering more data, on a greater number of analytes and in a shorter time – getting as much information as possible from each sample.

The increasing importance of biomarkers poses a number of challenges for the analytical laboratory. A large panel of biomarkers is often required to fully characterise a disease state and drug efficacy for a given condition. Ethical considerations and the requirements for clinical safety testing may impose practical limits on the number of samples that can be collected.

Dr Stovold commented: “Quotient Bioresearch was one of the commercial pioneers of biomarker analysis for clinical studies and pharmaceutical licensing. We now provide a number of multiplexing methods that dramatically increase the throughput of biomarker analysis. These include LC-MS/MS for small and large molecules, Meso Scale Discovery (MSD™), and Gyrolab® - a miniaturized open-technology immunoassay platform.”

Now in its fifth year, the Biomarker World Congress is dedicated to biomarker research and implementation. In Philadelphia, more than 400 delegates from pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers, were able to share experience, foster collaborations, and evaluate emerging technologies.

Ends

About Quotient Bioresearch

Quotient Bioresearch is part of the Quotient Bioscience Group, providing solutions for early phase discovery through to proof of concept clinical trails and laboratory services.

Quotient Bioresearch currently employs over 350 scientists and clinical research professionals working within purpose built, state-of-the-art laboratory facilities in Cambridgeshire and Northamptonshire. Quotient Clinical (a member of Quotient Bioresearch) provides specialist Phase I clinical services from its units in Nottingham and Edinburgh.

For further information: www.quotientbioscience.com 

For more information, please contact:

Michael van der Merwe, Business Development Manager, Quotient Bioresearch
Tel: +44 (0) 1638 720 500
Email: info@quotientbioresearch.com
Web: www.quotientbioresearch.com 

For press information, please contact:

Richard Kent, Director, Kapler Communications
Tel: +44 (0) 1480 479 280
Email: richard@kapleronline.com